In addition, increased frequencies of CD27+CD45RO-CD8+ T cells at the time of leukapheresis have been implicated to correlate with sustained remission in patients with chronic lymphocytic leukemia treated with CD19 CART cells (21), in multiple myeloma patients treated with B cell maturation antigen (BCMA)-specific CART cells (22), and recently in patients with DLBCL (23). This evidence concerns the gene CD8A and plasma cell myeloma.